Abstracts

SUBMISSION TYPES

CIS will accept both abstracts and case reports for the 2024 Annual Meeting. Submitters are required to to indicate which type of submission they have as part of the submission process. 

If submitting a case report, please indicate if it is a single case or is a case series as part of your abstract text. While addressing the specifics of the case(s) in the abstract, please try to state the broader impact of your work for the field of Clinical Immunology. 

GENERAL SUBMISSION GUIDELINES

• All abstracts must be submitted online, via the CIS abstract submission portal.
• You do not need to be a member of CIS to submit an abstract or case report.
• Submissions must be no longer than 350 words.
• CIS does not accept encore abstracts as part of the Annual Meeting.
• No patient photos may be submitted as part of the abstract or case report.
• Only charts/figures are allowed to be included with submissions. Charts/figures must be uploaded in .doc or .docx format.
• There is no requirement for formatting of the abstracts beyond what is listed above.
• If accepted for presentation at the meeting, the abstract will be published as submitted into the 2024 Annual Meeting supplement. However, the Editors reserve the right to edit any abstract that contains grammatical errors.

AUTHOR LISTING AND DISCLOSURE INFORMATION

Authors should be listed in the order you would like them published in the Annual Meeting supplement. Each Submitter will be asked to indicate one person as the presenting author for the submission, who will present if the abstract is selected for a poster or oral abstract presentation.

All listed authors are required to submit a disclosure form as part of their submission.  The disclosure form may be completed by the abstract/case report submitter, or the form can be sent to each author via the submission portal. 

ABSTRACT SUBMISSION TOPICS

Topics of interest for the 2024 Annual Meeting cover a wide range of topics. The list below, while not exhaustive, covers topics that attendees in the past have indicated a particular interest in.

• B Cell Biology
• Biological Mechanisms of PID
• Hematopoietic Cell Transplantation and Gene Therapy
• Immune Dysregulation in PID
• Immune Modulating Therapies
• Immunoglobulin Replacement Therapy
• Infections in PIDs
• Innate Immunity
• NK Cell Biology
• Novel Genetic Etiologies of PIDs
• Phenotypic and Molecular Spectrum of Primary Immune Deficiency
• Psychosocial and outcomes research in PID
• PID Registries
• PID and Aging
• PID and Cancer
• PID and COVID-19
• PID and Metabolism
• T Cell Biology
• Secondary IEIs
• Systems biology and 'omics of PID
• Other Topics Related To Immune Deficiency and/or Dysregulation

EMBARGO POLICY

Abstract titles and author lists are embargoed until a date and time determined by CIS. Abstract content is embargoed until the abstract supplement publication date and time. The embargo date for the 2024 Annual Meeting is May 1, 2024 at 8:00am. Any updated and/or new data that will be presented in a poster presentation or an oral presentation is embargoed until the time and date of the presentation.

Embargo requests outside of the set policies and any planned press releases and media alerts must be reviewed and approved in advance by CIS. Requests must be received in writing and should be sent to info@clinimmsoc.org.